Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02833857 · ClinicalTrials.gov registry record · Phase 1
A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT02833857 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 11 participants.
The verdict
NCT02833857, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is a study to evaluate the safety and pharmacokinetics in pediatric patients with secondary hyperparathyroidism receiving a single dose of etelcalcetide at the end of hemodialysis.
Interventions
- DRUG Etelcalcetide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-03-14 |
| Est. Completion | 2018-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02833857
The ClinicalTrials.gov registry entry for NCT02833857 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Etelcalcetide is the first listed.
NCT02833857 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02833857 about?
NCT02833857 is a clinical study titled "A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis". This is a study to evaluate the safety and pharmacokinetics in pediatric patients with secondary hyperparathyroidism receiving a single dose of etelcalcetide at the end of hemodialysis.
What is the current status of trial NCT02833857?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2017-03-14. Estimated completion is 2018-10-31.
What interventions are being tested in trial NCT02833857?
The interventions under investigation include: Etelcalcetide (DRUG).
Who is sponsoring clinical trial NCT02833857?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.